The Role of Pharmacists in Treating Very High-Risk ASCVD

Two recent graduates share strategies for standing out in the competitive fellowship application process.

Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.

In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.

Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.

This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.

Tucatinib’s new HER2-positive breast cancer maintenance indication extends disease control while requiring close liver monitoring and pharmacist coordination of oral therapy with ongoing antibody treatment.

Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.

This quiz was created in collaboration with PTCE™.